Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $216.0 million.

  • Enanta Pharmaceuticals' Total Liabilities fell 1284.02% to $216.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.0 million, marking a year-over-year decrease of 1284.02%. This contributed to the annual value of $216.0 million for FY2025, which is 1284.02% down from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Total Liabilities is $216.0 million, which was down 1284.02% from $221.8 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Total Liabilities peaked at $257.3 million during Q2 2023, and registered a low of $31.7 million during Q1 2021.
  • Its 5-year average for Total Liabilities is $147.5 million, with a median of $216.0 million in 2025.
  • In the last 5 years, Enanta Pharmaceuticals' Total Liabilities tumbled by 1692.4% in 2022 and then surged by 44533.7% in 2023.
  • Enanta Pharmaceuticals' Total Liabilities (Quarter) stood at $56.2 million in 2021, then decreased by 16.92% to $46.7 million in 2022, then skyrocketed by 406.7% to $236.6 million in 2023, then rose by 0.09% to $236.8 million in 2024, then decreased by 8.79% to $216.0 million in 2025.
  • Its Total Liabilities was $216.0 million in Q3 2025, compared to $221.8 million in Q2 2025 and $229.5 million in Q1 2025.